Condition
Metastatic Castration-Resistant Prostate Cancer Patients clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Metastatic Castration-Resistant Prostate Cancer Patients clinical trials that are recruiting, at sites in 2 countries (most in United States (2), China (2)). By phase: Phase 1 (4). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest Metastatic Castration-Resistant Prostate Cancer Patients clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| JANX013 and JANX007 combo in advanced prostate cancer | Phase 1 | Nashville, Tennessee | Recruiting | Sep 10, 2026 |
| TSL2109 capsules for advanced solid tumors, including treatment‑resistant prostate cancer | Phase 1 | Shanghai, Shanghai Municipality | Recruiting | Apr 7, 2026 |
| Testing [225Ac]Ac-PSMA-XT, a PSMA-targeted alpha therapy, in men with metastatic castration‑resistant prostate cancer. | Phase 1 | Jinan, Shandong | Recruiting | Aug 21, 2025 |
| KTX-2001 (alone and with darolutamide) for men with metastatic castration‑resistant prostate cancer | Phase 1 | San Francisco, California and 12 other locations | Recruiting | Aug 5, 2025 |
All recruiting trials (4)
-
JANX013 and JANX007 combo in advanced prostate cancer
A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.
-
TSL2109 capsules for advanced solid tumors, including treatment‑resistant prostate cancer
This trial tests whether the oral drug TSL2109 is safe, tolerable, and shows early signs of benefit for people with advanced solid tumors, especially those with metastatic castration‑resistant prostate cancer who have progressed after standard therapies.
-
Testing [225Ac]Ac-PSMA-XT, a PSMA-targeted alpha therapy, in men with metastatic castration‑resistant prostate cancer.
This will try a PSMA-targeted radioactive drug called [225Ac]Ac-PSMA-XT to see if it is safe and helps men with metastatic castration‑resistant prostate cancer.
-
KTX-2001 (alone and with darolutamide) for men with metastatic castration‑resistant prostate cancer
This trial tests whether KTX-2001, by itself and combined with darolutamide, can help men whose prostate cancer has spread and stopped responding to hormone therapies.
Related topics
Quick answers
How many Metastatic Castration-Resistant Prostate Cancer Patients clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (2 trials), China (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.